Lupin: Company Launches Topiramate Extended-Release Capsules In The U.S. With Estimated Annual Sales Of USD 164 Million

 04 Feb 2026 08:49 PM

Lupin: Company Launches Topiramate Extended-Release Capsules In The U.S. With Estimated Annual Sales Of USD 164 Million

Lupin: Co Launches Dasatinib Tablets In The U.S. After FDA Approval, Available In Dosages Of 20 MG, 50 MG, 70 MG, 80 MG, 100 MG, And 140 MG; Expected Annual Sales Reach USD 930 Million.

 02 Feb 2026 11:04 AM

Lupin: Co Launches Dasatinib Tablets In The U.S. After FDA Approval, Available In Dosages Of 20 MG, 50 MG, 70 MG, 80 MG, 100 MG, And 140 MG; Expected Annual Sales Reach USD 930 Million.

Lupin: Forms Partnership With TB Alliance To Develop Telacebec For Treating Tuberculosis And Other Mycobacterial Illnesses, Offering Manufacturing And Regulatory Support.

 02 Feb 2026 10:09 AM

Lupin: Forms Partnership With TB Alliance To Develop Telacebec For Treating Tuberculosis And Other Mycobacterial Illnesses, Offering Manufacturing And Regulatory Support.

Lupin: DGTR, In Its Preliminary Findings Concludes That There Is Dumping Of Ethambutol Hydrochloride Imports From China And Thailand, And Flags This As A Material Injury To Domestic Players

 01 Feb 2026 09:04 AM

Lupin: DGTR, In Its Preliminary Findings Concludes That There Is Dumping Of Ethambutol Hydrochloride Imports From China And Thailand, And Flags This As A Material Injury To Domestic Players

Lupin: Partners With :Galenicum For Semaglutide Licensing And Supply In 23 Nations

 21 Jan 2026 08:03 AM

Lupin: Partners With :Galenicum For Semaglutide Licensing And Supply In 23 Nations

Lupin: Company Approves Mr. Anand Kripalu's Appointment As Additional Non-Executive Independent Director Starting On February 01

 06 Jan 2026 09:22 PM

Lupin: Company Approves Mr. Anand Kripalu's Appointment As Additional Non-Executive Independent Director Starting On February 01

Lupin: Company Signs Exclusive Licensing Deal With Gan & Lee Pharmaceuticals For New GLP-1 Receptor Agonis

 29 Dec 2025 06:28 PM

Lupin: Company Signs Exclusive Licensing Deal With Gan & Lee Pharmaceuticals For New GLP-1 Receptor Agonis

Lupin: Company Partners With Neopharmed For Exclusive Licensing Of Gastroenterology Drug Plasil In Philippines And Brazil

 18 Dec 2025 05:04 PM

Lupin: Company Partners With Neopharmed For Exclusive Licensing Of Gastroenterology Drug Plasil In Philippines And Brazil

Lupin Limited: Gets Favorable Opinion From CHMP For Biosimilar Ranibizumab; Marketing Approval Suggested For Vial And Pre-Filled Syringe Forms; Sandoz Group AG To Manage Marketing In EU

 17 Dec 2025 11:50 AM

Lupin Limited: Gets Favorable Opinion From CHMP For Biosimilar Ranibizumab; Marketing Approval Suggested For Vial And Pre-Filled Syringe Forms; Sandoz Group AG To Manage Marketing In EU

Lupin: Company Gets EIR Approval From US FDA For Nagpur Injectable Plant

 16 Dec 2025 08:54 PM

Lupin: Company Gets EIR Approval From US FDA For Nagpur Injectable Plant

Lupin: Co Manufacturing Solutions Partners With Polypeptide To Expand Global Peptide Supply Chain

 12 Dec 2025 11:46 AM

Lupin: Co Manufacturing Solutions Partners With Polypeptide To Expand Global Peptide Supply Chain

Lupin: Company Gets Tentative Approval From U.S. FDA For Siponimod Tablets, Market Potential Estimated At $200 Million

 05 Dec 2025 09:27 AM

Lupin: Company Gets Tentative Approval From U.S. FDA For Siponimod Tablets, Market Potential Estimated At $200 Million

Lupin: Company Partners with Valorum for Exclusive Licensing Deal of Biosimilar Armlupeg in the U.S.

 04 Dec 2025 01:18 PM

Lupin: Company Partners with Valorum for Exclusive Licensing Deal of Biosimilar Armlupeg in the U.S.

Lupin: CITI on Lupin Buy, Price Target Rs 2260

 01 Dec 2025 09:10 AM

Lupin: CITI on Lupin Buy, Price Target Rs 2260

Lupin: Company And Several PE Firms, Including TPG And EQT, Are In Talks To Buy UK's Biggest Nutraceutical Firm Vitabiotics -ET

 01 Dec 2025 08:41 AM

Lupin: Company And Several PE Firms, Including TPG And EQT, Are In Talks To Buy UK's Biggest Nutraceutical Firm Vitabiotics -ET

Lupin: Company, TPG Capital, and EQT are Negotiating to Purchase Family-Owned Vitabiotics. - ET

 01 Dec 2025 08:23 AM

Lupin: Company, TPG Capital, and EQT are Negotiating to Purchase Family-Owned Vitabiotics. - ET

Lupin: Company Gains U.S. FDA Approval For Biosimilar Armlupeg (Pegfilgrastim-Unne) With Estimated Annual Sales Of $1.295 Billion In The U.S.

 01 Dec 2025 07:58 AM

Lupin: Company Gains U.S. FDA Approval For Biosimilar Armlupeg (Pegfilgrastim-Unne) With Estimated Annual Sales Of $1.295 Billion In The U.S.

Lupin: Jefferies on Lupin Buy, target price Rs 2300

 25 Nov 2025 09:02 AM

Lupin: Jefferies on Lupin Buy, target price Rs 2300

Lupin: Company Confirms FDA Inspection Closure Of Nagpur Unit-1 With No Issues Found

 15 Nov 2025 07:14 PM

Lupin: Company Confirms FDA Inspection Closure Of Nagpur Unit-1 With No Issues Found

Lupin: Unveils Risperidone Long-Acting Injectable With 180-Day CGT Exclusivity In The U.S., Marking The First Launch From Its PrecisionSphere Platform.

 14 Nov 2025 08:23 AM

Lupin: Unveils Risperidone Long-Acting Injectable With 180-Day CGT Exclusivity In The U.S., Marking The First Launch From Its PrecisionSphere Platform.